KPTI · Insider Trading
Karyopharm Therapeutics Inc.
Every open-market purchase and sale reported by KPTI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-19 | Kristin Abate | Chief Accounting Officer | Sell | −4,788 | −$1.65K |
| 2026-10-02 | Kristin Abate | Chief Accounting Officer | Sell | −378 | −$450 |
| 2026-09-02 | Kristin Abate | Chief Accounting Officer | Sell | −19 | −$38 |
| 2026-07-30 | Stuart Poulton | EVP, Chief Development Officer | Sell | −189 | −$1.34K |
| 2026-05-26 | Garen G Bohlin | Director | A | +15,508 | — |
| 2026-05-26 | Christy J. Oliger | Director | A | +15,508 | — |
| 2026-05-26 | Deepika Pakianathan | Director | A | +15,508 | — |
| 2026-05-26 | Chen Schor | Director | A | +15,508 | — |
| 2026-05-26 | Barry E Greene | Director | A | +15,508 | — |
| 2026-05-26 | Zhen Su | Director | A | +15,508 | — |
| 2026-05-15 | Michael Mano | EVP, CLO&Secretary | MIXED | +434 | −$2.53K |
| 2026-05-15 | Kristin Abate | Chief Accounting Officer | MIXED | +68 | −$504 |
| 2026-05-15 | Stuart Poulton | EVP, Chief Development Officer | MIXED | +493 | −$3.83K |
| 2026-05-15 | Sohanya Roshan Cheng | EVP & Chief Commercial Officer | MIXED | +623 | −$3.08K |
| 2026-05-15 | Reshma Rangwala | EVP & Chief Medical Officer | MIXED | +539 | −$3.88K |
| 2026-05-15 | Richard A. Paulson | President and CEO | MIXED | +2,717 | −$20.93K |
| 2026-04-22 | Reshma Rangwala | EVP & Chief Medical Officer | Sell | −449 | −$4.01K |
| 2026-03-03 | Kristin Abate | Chief Accounting Officer | Sell | −559 | −$5.26K |
| 2026-03-03 | Richard A. Paulson | President and CEO | Sell | −12,361 | −$116.31K |
| 2026-03-03 | Reshma Rangwala | EVP & Chief Medical Officer | Sell | −5,066 | −$47.67K |
| 2026-03-03 | Stuart Poulton | EVP, Chief Development Officer | Sell | −5,101 | −$48.00K |
| 2026-03-03 | Sohanya Roshan Cheng | EVP & Chief Commercial Officer | Sell | −4,604 | −$43.32K |
| 2026-03-03 | Michael Mano | EVP, CLO&Secretary | Sell | −3,526 | −$33.18K |
| 2026-02-19 | Stuart Poulton | EVP, Chief Development Officer | Sell | −378 | −$3.26K |
| 2026-02-09 | Richard A. Paulson | President and CEO | A | +81,060 | — |
| 2026-02-04 | Lori Macomber | EVP, CFO & Treasurer | Sell | −1,626 | −$10.24K |
| 2026-02-03 | Stuart Poulton | EVP, Chief Development Officer | A | +32,415 | — |
| 2026-02-03 | Sohanya Roshan Cheng | EVP & Chief Commercial Officer | A | +32,415 | — |
| 2026-02-03 | Michael Mano | EVP, CLO&Secretary | A | +32,415 | — |
| 2026-02-03 | Reshma Rangwala | EVP & Chief Medical Officer | A | +32,415 | — |
| 2026-02-03 | Lori Macomber | EVP, CFO & Treasurer | A | +32,415 | — |
| 2026-01-29 | Kristin Abate | Chief Accounting Officer | MIXED | +42 | −$352 |
| 2026-01-22 | Kristin Abate | Chief Accounting Officer | Sell | −265 | −$1.58K |
| 2025-10-16 | Stuart Poulton | EVP, Chief Development Officer | A | +39,682 | — |
| 2025-10-16 | Sohanya Roshan Cheng | EVP & Chief Commercial Officer | A | +43,650 | — |
| 2025-10-16 | Michael Mano | SVP, General Counsel&Secretary | A | +43,650 | — |
| 2025-10-16 | Kristin Abate | Chief Accounting Officer | A | +12,799 | — |
| 2025-10-16 | Richard A. Paulson | President and CEO | A | +114,285 | — |
| 2025-10-16 | Lori Macomber | EVP, CFO & Treasurer | A | +43,650 | — |
| 2025-10-03 | Kristin Abate | Chief Accounting Officer | Sell | −362 | −$2.28K |
| 2025-09-16 | Reshma Rangwala | EVP & Chief Medical Officer | MIXED | +537 | −$2.62K |
| 2025-09-16 | Sohanya Roshan Cheng | EVP & Chief Commercial Officer | MIXED | +620 | −$2.09K |
| 2025-09-16 | Kristin Abate | Chief Accounting Officer | MIXED | +23 | −$148 |
| 2025-09-16 | Richard A. Paulson | President and CEO | MIXED | +1,543 | −$8.08K |
| 2025-09-16 | Stuart Poulton | EVP, Chief Development Officer | MIXED | +487 | −$2.58K |
| 2025-09-16 | Michael Mano | SVP, General Counsel&Secretary | MIXED | +378 | −$1.50K |
| 2025-09-04 | Kristin Abate | Chief Accounting Officer | Sell | −12 | −$81 |
| 2025-07-30 | Stuart Poulton | EVP, Chief Development Officer | Sell | −191 | −$835 |
| 2025-07-23 | Kristin Abate | Chief Accounting Officer | Sell | −238 | −$952 |
| 2025-05-29 | Zhen Su | Director | A | +4,600 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Richard A. Paulson | President and CEO | 269,747 | $130.05K |
| Sohanya Roshan Cheng | EVP & Chief Commercial Officer | 108,264 | $52.19K |
| Stuart Poulton | EVP, Chief Development Officer | 94,632 | $45.62K |
| Michael Mano | EVP, CLO&Secretary | 94,398 | $45.51K |
| Lori Macomber | EVP, CFO & Treasurer | 85,105 | $41.03K |
| Reshma Rangwala | EVP & Chief Medical Officer | 56,829 | $27.40K |
| Deepika Pakianathan | Director | 30,795 | $14.85K |
| Kristin Abate | Chief Accounting Officer | 18,616 | $8.97K |
| Garen G Bohlin | Director | 18,517 | $8.93K |
| Barry E Greene | Director | 16,415 | $7.91K |
| Chen Schor | Director | 15,508 | $7.48K |
| Christy J. Oliger | Director | 15,508 | $7.48K |
| Zhen Su | Director | 15,508 | $7.48K |
| Mansoor Raza Mirza | Director | 808 | $390 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the KPTI quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.